1. Longitudinal Molecular and Serological Evidence of SARS-CoV-2 Infections and Vaccination Status: Community-Based Surveillance Study (CONTACT)

   • Olga Sánchez-Soliño
   • Ryan D. Kilpatrick
   • Gregory C. Gray

   Brief Report Open access 10 March 2024 Pages: 633 - 645

   

2. Toxic-Induced Encephalopathy Following Chemsex in a Young HIV-Positive Male: A Complex Case of Acute Cognitive Impairment with Anterograde Amnesia and Behavioral Alterations

   • Alexy Inciarte
   • Lorena de la Mora
   • Josep Mallolas

   Case Report Open access 03 April 2024 Pages: 647 - 658

   

3. Podcast: Need for Quality Evidence for Decision-Making on Seasonal Influenza Vaccines

   • Ann R. Falsey
   • Stefania Maggi
   • Tor Biering-Sørensen

   Commentary Open access 14 March 2024 Pages: 659 - 666

4. Epidemiology of Reportable Bacterial Infectious Diseases in Saudi Arabia

   • Nada K. Alhumaid
   • Areej M. Alajmi
   • Essam A. Tawfik

   Original Research Open access 10 March 2024 Pages: 667 - 684

5. Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey

   • Jennie H. Best
   • Mitra Sadeghi
   • Marcus J. Zervos

   Original Research Open access 14 March 2024 Pages: 685 - 697

   

6. Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination

   • Timothy E. Albertson
   • Caitlin Hansen
   • the C4591031, C4591007 Clinical Trial Groups

   Original Research Open access 15 March 2024 Pages: 699 - 714

   

7. K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact

   • Carolina Garcia-Vidal
   • Christian Teijón-Lumbreras
   • Alex Soriano

   Original Research Open access 15 March 2024 Pages: 715 - 726

   

8. Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study

   • Zhikai Wan
   • Junwei Su
   • Biao Zhu

   Original Research Open access 15 March 2024 Pages: 727 - 744

   

9. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

   • Mark H. Rozenbaum
   • Erica Chilson
   • Mark Atwood

   Original Research Open access 16 March 2024 Pages: 745 - 760

   

10. Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia

    • Ru Han
    • Peter San Martin
    • Désirée A. M. van Oorschot

    Original Research Open access 17 March 2024 Pages: 761 - 778

    

11. Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework

    • Sushma Kavikondala
    • Katrin Haeussler
    • Ekkehard Beck

    Original Research Open access 18 March 2024 Pages: 779 - 811

    

12. Evaluating the Demand for Nucleic Acid Testing in Different Scenarios of COVID-19 Transmission: A Simulation Study

    • Yu-Yuan Wang
    • Wei-Wen Zhang
    • Ming-xia Jing

    Original Research Open access 18 March 2024 Pages: 813 - 826

    

13. Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States

    • Daniel Molnar
    • Elizabeth M. La
    • Desmond Curran

    Original Research Open access 20 March 2024 Pages: 827 - 844

    

14. Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019

    • Aleksandra Polkowska-Kramek
    • Elizabeth Begier
    • Gernot Rohde

    Original Research Open access 23 March 2024 Pages: 845 - 860

15. Impact of Immunosuppressed Status on Prognosis of Carbapenem-Resistant Organisms Bloodstream Infections

    • Yuan-Yuan Li
    • Yan Chen
    • Bin Du

    Original Research Open access 27 March 2024 Pages: 861 - 874

    

16. Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses

    • Paul Benson
    • Jennifer Kuretski
    • Alan Oglesby

    Original Research Open access 03 April 2024 Pages: 875 - 889

    

17. Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study

    • Stefan Schneider
    • Gary Blick
    • Alan Oglesby

    Original Research Open access 03 April 2024 Pages: 891 - 906

    

18. Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany

    • Sebastian Gruhn
    • Manuel Batram
    • Oliver Damm

    Original Research Open access 04 April 2024 Pages: 907 - 920

    

19. Best Practices for Identifying Hospitalized Lower Respiratory Tract Infections Using Administrative Data: A Systematic Literature Review of Validation Studies

    • Germaine Hanquet
    • Christian Theilacker
    • Elizabeth Begier

    Review Open access 18 March 2024 Pages: 921 - 940

    

20. Effect of Infusion Set Replacement Intervals on Central Line-Associated Bloodstream Infection in the Intensive Care Unit: Study Protocol of the INSPIRATION Study

    • Dandan Xu
    • Chang Hu
    • On behalf of the INSPIRATION Study group

    Study Protocol Open access 14 March 2024 Pages: 941 - 951

    

21. Estimation of Symptomatic Respiratory Syncytial Virus Infection Incidence in Adults in Multiple Countries: A Time-Series Model-Based Analysis Protocol

    • Robin Bruyndonckx
    • Aleksandra Polkowska-Kramek
    • Elizabeth Begier

    Study Protocol Open access 18 March 2024 Pages: 953 - 963